6月2日 演題レポート
PHS=Poster Highlights Session,
GPS=General Poster Session,
CSS=Clinical Science Symposia
Abstract #3500
Preoperative Chemoradiotherapy and Postoperative Chemotherapy with 5-FU and Oxaliplatin versus 5-FU Alone in Locally Advanced Rectal Cancer: Results of the CAO/ARO/AIO-04 Randomized Phase III Trial
Claus Rödel, et al.
Abstract #3501
Preoperative Chemoradiotherapy and Postoperative Chemotherapy with Capecitabine + Oxaliplatin vs. Capecitabine Alone in Locally Advanced Rectal Cancer: Early Results of the PETACC 6 Trial
Hans-Joachim Schmoll, et al.
Abstract #3502
Adjuvant Chemotherapy with FOLFOX vs. FL for Rectal Cancer Patients Whose Postoperative Stage of ypII/III after Preoperative Chemoradiotherapy: results of 3-year Disease-free Survival from a Randomised Phase II Study (The ADORE)
Yong Sang Hong, et al.
Abstract #3503
Maintenance Strategy with Fluoropyrimidines (FP) Plus Bevacizumab (Bev), Bev Alone, or No Treatment, Following a Standard Combination of FP, Oxaliplatin (Ox), and Bev as 1st-line Treatment for Patients with Metastatic Colorectal Cancer (mCRC): A Non-inferiority Phase III Trial (AIO 0207)
Dirk Arnold, et al.
Abstract #3504
Final Results and Subgroup Analyses of the Phase 3 CAIRO3 Study: Maintenance Treatment with Capecitabine + Bevacizumab Versus Observation after Induction Treatment with Chemotherapy + Bevacizumab in Metastatic Colorectal Cancer
Miriam Koopman, et al.
Abstract #3506 / #3505
Abstract #3506
Treatment Outcome According to Tumor RAS Mutation Status in CRYSTAL Study Patients with Metastatic Colorectal Cancer (mCRC) Randomized to FOLFIRI with/without Cetuximab
Fortunato Ciardiello, et al.
Abstract #3505
Treatment Outcome According to Tumor RAS Mutation Status in OPUS Study Patients with Metastatic Colorectal Cancer (mCRC) Randomized to FOLFOX4 with/without Cetuximab
Carsten Bokemeyer, et al.
Abstract #3507
Prognostic Impact of Defective Mismatch Repair in Stage II/III Colon Cancer: A Pooled Individual Patient Data Analysis of 17 Adjuvant Trials from the ACCENT Database
Daniel J. Sargent, et al.
Abstract #3508
Impact of Adjuvant Chemotherapy with 5-FU or FOLFOX in Colon Cancers with Microsatellite Instability: An AGEO Multicenter Study
David Tougeron, et al.
Abstract #4000
A Randomized Double-blind Phase II Study of Ruxolitinib (RUX) or Placebo (PBO) with Capecitabine (CAPE) as 2nd-line Therapy in Patients (pts) with Metastatic Pancreatic Cancer (mPC)
Herbert Hurwitz, et al.
Abstract #4003
Phase III Study of Apatinib in Metastatic Gastric Cancer: A Randomized, Double-blind, Placebo-controlled Trial
Shukui Qin, et al.
Abstract #4004
Ramucirumab Combined with FOLFOX as Front-line Therapy for Advanced Adenocarcinoma of Esophagus, Gastroesophageal Junction, or Stomach: Randomized, Double-blind, Multicenter Phase II Trial
Harry H Yoon, et al.
Abstract #4005
RAINBOW: A Global, Phase III, Randomized, Double-blind Study of Ramucirumab Plus Paclitaxel Versus Placebo Plus Paclitaxel in the Treatment of Metastatic Gastroesophageal Junction and Gastric Adenocarcinoma Following Disease Progression on First-line Platinum- and Fluoropyrimidine-Containing Combination Therapy: Efficacy Analysis in Japanese and Western Patients
Shuichi Hironaka, et al.
Abstract #4006
STORM: A Phase III, Randomized, Double-blind, Placebo-controlled Trial of Adjuvant Sorafenib after Resection or Ablation to Prevent Recurrence of Hepatocellular Carcinoma
Jordi Bruix, et al.
Abstract #4008
Phase III Trial to Compare Adjuvant Capecitabine/Cisplatin (XP) versus XP plus Concurrent Capecitabine-radiotherapy (XRT) in Gastric Cancer (GC) : The Final Report of the ARTIST Trial
Jeeyun Lee, et al.